Vascular Endothelial Growth Factor in Pulmonary Hypertension

The best studied of the endothelial cell specific growth factors, VEGF, is present in alveolar and bronchial epithelial cells, in vascular smooth muscle cells, and in macrophages. The gene encoding VEGF is abundantly present in lung tissue and is induced by short-term and long-term hypoxia, as well as by prostacyclin, prostaglandin E2, and cyclic AMP. In the case of prostaglandin-stimulated gene upregulation protein kinase A (PKA) is involved. Suramin, an inhibitor of growth factor receptor binding inhibits the development of chronic hypoxic pulmonary hypertension in rats. Further evidence is necessary to link VEGF with pulmonary hypertensive vascular remodeling. This requires the development of antibodies directed against VEGF or against VEGF receptors and gene transfection or antisense strategies.

[1]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[2]  N. Voelkel,et al.  Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. , 1995, The Journal of clinical investigation.

[3]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[4]  M. Hosang.  Suramin binds to platelet‐derived growth factor and inhibits its biological activity , 1985, Journal of cellular biochemistry.

[5]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[6]  G. Breier,et al.  Hypoxia and platelet‐derived growth factor‐BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells , 1995, FEBS letters.

[7]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[8]  T. Quinn,et al.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.

[10]  M. Wilkinson,et al.  A pathophysiological study of 10 cases of hypoxic cor pulmonale. , 1988, The Quarterly journal of medicine.

[11]  S. Rodan,et al.  Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. , 1994, The Journal of clinical investigation.

[12]  H. Sinzinger.  Prostacyclin and Iloprost — Thrombosis and Atherosclerosis , 1987 .

[13]  D. Heath,et al.  Pulmonary vascular remodelling in a high-altitude Aymara Indian , 1991, International journal of biometeorology.

[14]  H. Dvorak,et al.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. , 1992, Molecular biology of the cell.

[15]  M. Shibuya,et al.  Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.

[16]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[17]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[18]  E. Oldfield,et al.  Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. , 1993, The American journal of physiology.

[19]  J. Winer,et al.  Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. , 1992, The Journal of clinical investigation.

[20]  T. Higenbottam,et al.  Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). , 1987, British heart journal.

[21]  Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. , 1992, British Journal of Cancer.